Chimeric Therapeutics Limited
CHMMF
$0.001
-$0.029-96.67%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -2.75% | 260.77% | |||
| Total Revenue | -2.75% | 260.77% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.75% | 260.77% | |||
| SG&A Expenses | -2.75% | -12.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -27.41% | |||
| Operating Income | 2.75% | 81.99% | |||
| Income Before Tax | 2.75% | 81.43% | |||
| Income Tax Expenses | -2.81% | 69.85% | |||
| Earnings from Continuing Operations | 2.75% | 80.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 80.59% | |||
| EBIT | 2.75% | 81.99% | |||
| EBITDA | 2.75% | 84.68% | |||
| EPS Basic | 10.00% | 83.05% | |||
| Normalized Basic EPS | 0.00% | 84.62% | |||
| EPS Diluted | 10.00% | 83.05% | |||
| Normalized Diluted EPS | 0.00% | 84.62% | |||
| Average Basic Shares Outstanding | 0.00% | 20.56% | |||
| Average Diluted Shares Outstanding | 0.00% | 20.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||